Merck's MilliporeSigma agrees to acquire Mirus Bio for $600m [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
The move aims to enhance Merck's capabilities in viral vector manufacturing for cell and gene therapies. MilliporeSigma specialises in developing and commercialising transfection re-agents known as TransIT-VirusGEN, which are crucial for introducing genetic material into cells. The re-agents are pivotal in manufacturing viral vectors, a key component in the development of cell and gene therapies. Merck's Life Science business sector provides the pharmaceutical industry with high-grade chemicals, vital tools and consumables to expedite scientific discoveries. The acquisition will aid Merck in offering comprehensive solutions for every stage of viral vector manufacturing and support the advancement of cell and gene therapies from preclinical phases to commercial production. Merck's expertise spans viral vector types including adeno-associated virus, lentivirus and adenovirus. The company provides contract testing services and extensive contract development and manufacturing
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.MarketBeat
- Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand [Yahoo! Finance]Yahoo! Finance
- With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of ObesityBusiness Wire
- Trailhead Biosystems Announces Joshua Snow as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 8/8/24 - Miss
ARWR
Sec Filings
- 8/8/24 - Form 8-K
- 8/8/24 - Form 10-Q
- 7/3/24 - Form 4
- ARWR's page on the SEC website